Gastric precancerous conditions

Papers on gastric precancerous conditions

3 papers

Tuesday, October 6

Monday, October 5

Monday, March 9

Cancer Prevention Research

Eflornithine may lower a DNA damage marker in stomach lesions

Between months 18 and 24, after treatment ended, DNA damage marker scores fell 18.3 points with eflornithine versus 1.6 with placebo.Between months 18 and 24, after treatment ended, DNA damage marker scores fell 18.3 points with eflornithine versus 1.6 with placebo.

Randomized trial · 55 peopleInterventions